source
- Ultragenyx cuts 20% of workforce and abandons Wilson disease gene therapy after mixed Q3 resultsUltragenyx said it will cut about 20% of its workforce, marking a second round of layoffs this year. The reductions will affect roughly a fifth of the company's employees. At the same time, the fi…
- Pfizer partners with Sciwind to launch GLP-1 obesity drug Ecnoglutide in ChinaPfizer is entering China's obesity market with a new GLP-1 drug, Ecnoglutide, in partnership with Sciwind Biosciences. The New York-based company secured mainland China licensing rights to the inj…